(miRNAs) regulate gene expression at the post-transcriptional level and play important roles in tumor initiation and progression. Recently, we examined the global miRNA expression profile of esophageal squamous cell carcinoma (ESCC) and demonstrated that miR-92a was highly expressed in tumor tissues. In this study, we found that the upregulation of miR-92a was significantly correlated with the status of lymph node metastasis and TNM stage in 107 ESCC patients. Moreover, the upregulation of miR92a was associated with poor survival of ESCC patients and might be used as an independent prognostic factor. Next, we investigated the role and mechanism of miR-92a in ESCC cells, and found that miR-92a modulated the migration and invasion but not apoptosis and proliferation of ESCC cells in vitro. We further demonstrated that miR-92a directly targeted the CDH1 3'UTR and repressed the expression of CDH1, a tumor metastasis suppressor. In addition, restoring of miR-92a-resistant CDH1 expression in miR-92a-overexpression cells recovered the pro-metastasis activity of miR92a. Taken together, we demonstrated that miR-92a promotes ESCC cell migration and invasion at least partially via suppression of CDH1 expression, and patients with upregulated miR-92a are prone to lymph node metastasis and thus have poor prognosis.
microRNAs
(miRNAs) regulate gene expression at the post-transcriptional level and play important roles in tumor initiation and progression. Recently, we examined the global miRNA expression profile of esophageal squamous cell carcinoma (ESCC) and demonstrated that miR-92a was highly expressed in tumor tissues. In this study, we found that the upregulation of miR-92a was significantly correlated with the status of lymph node metastasis and TNM stage in 107 ESCC patients. Moreover, the upregulation of miR92a was associated with poor survival of ESCC patients and might be used as an independent prognostic factor. Next, we investigated the role and mechanism of miR-92a in ESCC cells, and found that miR-92a modulated the migration and invasion but not apoptosis and proliferation of ESCC cells in vitro. We further demonstrated that miR-92a directly targeted the CDH1 3'UTR and repressed the expression of CDH1, a tumor metastasis suppressor. In addition, restoring of miR-92a-resistant CDH1 expression in miR-92a-overexpression cells recovered the pro-metastasis activity of miR92a. Taken together, we demonstrated that miR-92a promotes ESCC cell migration and invasion at least partially via suppression of CDH1 expression, and patients with upregulated miR-92a are prone to lymph node metastasis and thus have poor prognosis.
Esophageal cancer is the eighth most common cancer and the sixth most common cause of cancer deaths worldwide. The incidence of esophageal cancer varies greatly by geographic location, where it is most common in China, Southeast Africa, and Japan. Compared with the high incidence of Barrett's associated adenocarcinoma in Europe and the United States (1), the incidence of esophageal squamous cell carcinoma (ESCC) is prevalent in China. Despite the advances in therapy, ESCC is still one of the most lethal malignancies in China, with an overall 5-year survival rate of 20-30% after surgery (2, 3) .
Tumor metastasis is primarily responsible for ESCC mortality, yet the molecular mechanism of metastatic dissemination remains unclear (4) . Recent evidences suggest that miRNAs play an important role in tumor metastasis (5) (6) (7) (8) . miRNA is the noncoding RNA of ~22 nucleotides which regulates gene expression via degradation of target mRNAs or inhibition of protein translation. Hundreds of miRNAs have been identified and some of them exhibit highly specific expression patterns in various tissues and species. More than 50% of annotated human miRNA genes are located in fragile chromosomal regions that are susceptible to amplification, deletion or translocation during the process of tumor development and can function either as oncogene or tumor suppressor (9) . miR-92a belongs to the miR-17-92a cluster and is located on chromosome 13q32-33, a region frequently amplified in B-cell lymphoma (10, 11) , lung cancer (12) and colorectal cancer (13) . The polycistronic miR-17-92a cluster produces six mature miRNAs (miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92a-1).
Upregulation of these miRNAs were found in B-cell lymphoma and lung, colon, breast, pancreas, prostate, stomach, liver, thyroid and nasopharyngeal tumors (12) (13) (14) (15) (16) (17) (18) .
Thus, these miRNAs are predicted to regulate different cellular targets for tumorigenesis in various organs, but the oncogenic contribution of each individual miRNA in this cluster has not been fully characterized. Several recent studies suggest that aberrant expression of miR-92a is relevant to embryonic development and tumorigenesis (19) (20) (21) . Previously, we reported that miR-92a is highly expressed in tumor tissues from ESCC patients (22) . In the present study, we investigated whether the relative expression of miR-92a between tumor and normal tissues is correlated with lymph node metastasis in ESCC patients and the mechanism by which miR-92a promotes ESCC metastasis. miRNA and mRNA Quantification-Total miRNA was isolated from frozen tissues using a mirVana miRNA isolation kit (Ambion). Total RNA was isolated from cultured cells using TRIzol reagent (Invitrogen). The first strand cDNA was synthesized using RevertAid first strand cDNA synthesis kit (Fermentas), which was then amplified with mirVana qRT-PCR primers sets (Ambion) by using TaqMan gene expression master mix (Applied Biosystems) and Applied Biosystems 7300 Real Time PCR system following the manufacturer's instructions. RNU6B served as internal control. All PCR reactions, including no-template controls, were performed in triplicate. The relative expression of miR-92 was calculated as 2 -(ΔCt T-ΔCt NAT)
EXPERIMENTAL PROCEDURES
. The 75 th percentiles of 2 -△△Ct was used as the cutoff point for patients with high and low levels of miR-92a. The levels of CDH1 transcript were measured by forward primer, 5'-AGAACGCATTGCCACATACA-3', and reverse primer, 5'-TGCTTAACCCCTCACCTTGA-3'. β-actin was used as internal control and amplified with forward primer, 5'-CGCGAGAAGATGACCCAGATC-3', and reverse primer, 5'-TGGTACGGCCAGAGGCG-3'.
Northern Blot-RNAs were denatured at 55°C for 30 min with deionized formamide. Total RNA (20 μg) or enriched total miRNA (5 μg) per lane was loaded onto a 15% polyacrylamide TBE gel and separated using 0.5× TBE as a running buffer at 14 mA for 3 h. After electrophoresis, the RNA was transferred to an N + membrane (Amersham) at 200 mA for 2 h by an electro-transferring system, and then it was crosslinked with ultraviolet radiation for 150 s, followed by baking it at 80°C for 1 h. Blots were pre-hybridized for 2 h at 37°C using hybridization buffer (BioDev) in hybridization tubes. Subsequently γ-32 P-end-labeled miRNA probes was added into tubes and incubated for 16 h at 37°C. After hybridization, the membranes were washed twice for 5 min using buffer 1 (0.1% SDS, 1×SSC) at room temperature and for 10 min using buffer 2 (0.1% SDS, 0.5×SSC) at 37°C and then exposed to X films for 72 h at -70°C. RNU6 was used as loading control. The probes were synthesized by Invitrogen and the probe sequence for miR-92a was 5'-ACAGGCCGGGACAAGUGCAAUACCAGAG -3'; the probe sequence for RNU6 was: 5'-CACGAAUUUGCGUGUCAUCCUUCCAGAG -3'. Antibodies, Western Blotting, and Immunohistochemistry-Anti-E-Cadherin (CDH1) (Cat#1702-1) and anti-GAPDH were purchased from Epitomics. HRP-labeled goat anti-rabbit IgG and anti-mouse IgG were purchased from Abgent. Western blotting was performed as previously described (23) . IHC was performed on 4 μm FFPE sections with anti-CDH1 as described (23) . Briefly, the slides were deparaffinized, rehydrated, and dripped in 3% hydrogen peroxide solution for 10 min. Following treatment with 10% goat serum at 37°C for 30 min, the slides were incubated with anti-CDH1 (1:600 dilution) at 37°C for 2 h. After washed with PBS, the slides were incubated with Polymer Helper for 20 min at room temperature, followed by polyperoxidase-antimouse/rabbit IgG at room temperature for 30 min. Development of the slides was carried out using DAB solution. Counterstaining was carried out with hematoxylin.
Negative control was performed by substituting the primary antibody with PBS incubation. IHC analysis was carried out by two pathologists without previous knowledge of patient information. The staining intensity was scored as follows: 0 (negative), 1 (weak), 2 (moderate), and 3(strong).
The percentage of positive cells was assigned to one of the following categories: 0 (0%-5%), 1 (6%-25%), 2 (26%-50%), 3 (51%-74%), or 4 (75%-100%). The two scores were then multiplied to produce a weighted score for each sample, the expression was considered positive when the score was > 2.
Cell Culture and Transfection-Five human ESCC cell lines (KYSE150, KYSE410, KYSE450, KYSE510, and EC9706) were cultured in RPMI-1640 medium (Hyclone) with 10% FBS (Hyclone) supplemented with 0.2% penicillin-streptomycin (Invitrogen). miR-92a precursor (pre-miR-92a), miR-92a inhibitor (anti-miR-92a) and FAMlabeled pre-miR and anti-miR negative control (pre-miR-nc, anti-miR-nc) were purchased from Ambion, and transfected at a final concentration of 30 nM with Lipofectmine 2000 (Invitrogen) following the manufacture's instruction. siRNA against CDH1 (Oligo ID: HSS101669) and scrambled siRNA negative control were purchased from Invitrogen and transfected at a final concentration of 40 nM.
Cell Proliferation, Apoptosis, Migration and Invasion Assay-To measure cell proliferation, cells were plated at a density of 1×10 3 cells per well onto 96-well plates at day 0 (24 h after premiR-92a or anti-miR-92a transfection open reading frame without 3'UTR, was purchased from OriGene Technologies. To restore the miR-92a-resistant CDH1 expression, KYSE410 cells were plated in 24-well plate and transfected with pre-miR-92a and pCMV6-ENTRY-CDH1 (1μg). Twenty-four hours after transfection, cells were digested and subjected to the migration and invasion assay as discussed above.
Luciferase Reporter Assay-Reporter construct s were modified from the pMIR plasmid (Ambion). The truncated element of CDH1 mRNA 3'UTR (136 bp) containing predictive miR-92 binding see d sequence was synthesized by Invitrogen and clo ned directly downstream of the firefly luciferase g ene to create the pMIR-CDH1-Wt plasmid. Site sp ecific mutated reporter plasmid (pMIR-CDH1-Mut) was then generated with QuikChange site-directed mutagenesis kit (Stratagene). Site specific mutati on forward and reverse primers are: 5'-AGGCTGG AGTGCAGTGGTTTAATCACAGCTCACTGCAG-3'; 5'-CTGCAGTGAGCTGTGATTAAACCACTGC ACTCCAGCCT-3'. Renilla luciferase expression c onstruct (phRL-TK) was used as internal control (Promega). pMIR-CDH1-Wt/-Mut (200 ng per we ll in 24-well plate) along with control phRL-TK (4 ng per well) were transfected after 24 h transfecti on of pre-miR-nc or anti-miR-92a. Twenty-four h ours later, cells were harvested and lysed with pass ive lysis buffer (Promega). Luciferase activity wa s measured by a dual-luciferase reporter system (P romega) using LB 960 Centro (Berthold). The lu minescence intensity of Firefly luciferase was nor malized to that of Renilla luciferase.
Statistical Analysis-Unpaired Student's t test was used with p < 0.05 considered significant. Results were displayed as mean ± S.E. from at least triplicate experiments for each group. All statistical analyses were performed with SPSS 13.0 software.
RESULTS

Expression of miR-92a is Correlated with Lymph Node Metastasis and TNM Stage in ESCC
Patients-The expression of miR-92a in ESCC tissues was detected by qRT-PCR and partially validated by Northern Blot (supplemental Fig. S1 ). Then, the relationship between relative expression of miR-92a and clinicopathologic information of ESCC patients was analyzed.
The relative expression of miR-92a significantly increased in patients with lymph node metastasis compared with patients without lymph node metastasis (p= 0.001) (Fig. 1A and Table 1 ). The relative expression of miR-92a in ESCC samples was also found to be correlated with the TNM stage of patients (p= 0.049) (Fig. 1A and Table 1 ). No significant association was found between miR-92a expression and other clinical characteristics such as age, gender, differentiation grade, gross pathological type, tumor position, and T classification (Table 1) .
High Level of miR-92a is Correlated with Poor Survival of ESCC Patients-The potential of miR-92a as a prognosis marker was further investigated in 65 patients.
These patients underwent ESCC resection during 1998 to 2002 and their 5-year follow-up information was available for each patient. This subgroup of patients had similar clinical characteristics as compared with the total 107 patients. KaplanMeier survival estimate showed that the patients with high miR-92a expression had a shorter survival compared with the patients with low miR92a expression. The difference in the prognosis of these two groups was statistically significant (p = 0.004; log-rank test) (Fig. 1B) . Next, univariate Cox analysis was performed to determine whether overall survival is associated with other prognostic factors, including differentiation grade, T, N, and TNM stages. We found that overall survival was correlated with miR-92a expression and N and TNM stages, but not differentiation grade and T stage (Table 1) . Furthermore, multivariate Cox proportional hazard regression analysis was performed using all four variables and showed that high miR-92a expression was an unfavorable prognostic factor (p= 0.032; risk ratio 2.198; 95% confidence interval, 1.030-4.673) along with TNM stage (p= 0.042; risk ratio 3.706; 95% confidence interval, 1.079-5.155) ( Table 2) .
miR-92a Modulates Migration and Invasion but not Proliferation in ESCC Cells-To investigate the mechanism by which miR-92a promotes lymph node metastasis, we examined the role of miR-92a in ESCC cell migration and invasion. The expression of miR-92a was dramatically increased by transfection of pre-miR-92a into KYSE410 cells and decreased by transfection of anti-miR-92a into EC9706 cells ( Fig. 2A and 2B , right panels). It was found that overexpression of miR-92a markedly enhanced migration of KYSE410 cells compared with negative control (Fig. 2A) . Conversely, the inhibition of miR-92a expression led to considerable decrease of the migration of EC9706 cells compared with the negative control (Fig. 2B) . Next, we examined the effect of miR-92a on cell invasion across an extracellular matrix and showed that in KYSE410 cells, overexpression of miR-92a markedly enhanced the potential of invasion compared with the control (Fig. 2C) . However, overexpression of miR-92a in KYSE410 cells and knock-down of miR-92a in EC9706 cells had no significant effect on cell apoptosis and proliferation ( Fig. 2D and  2E ). These results demonstrated that miR-92a promotes ESCC cell migration and invasion but has no effect on cell apoptosis and proliferation.
Expression of CDH1 is Regulated by miR-92a in ESCC cells and Inversely Correlated with the miR-92a Level in ESCC Tissues-
The activity of miR-92a to promote cell migration and invasion might be due to its ability to regulate the expression of genes contributed to metastatic dissemination. So we utilized bioinformatics analyses available on the web, including Pictar, TargetScan, miRanda, miRBase and MicroCosm Targets to predict the putative miR-92a targets that may contribute to metastasis. Three of them (TargetScan, miRanda and MicroCosm) predicted that CDH1 might be a target for miR-92a, and the 3' UTR of CDH1 mRNA contains a highly conserved binding site from position 499 to 524 for miR-92a (Fig 3A) . To determine whether CDH1 was the target of miR-92a, the relationship between miR-92a expression and CDH1 level was analyzed. It was found that there was a strong inverse relationship between miR-92a expression and CDH1 protein level in five ESCC cell lines (r= -0.870, p= 0.028) (Fig. 3B) . Moreover, the overexpression of miR-92a could significantly down-regulate the level of CDH1 protein in KYSE410 cells. Conversely, the level of CDH1 protein was markedly up-regulated by suppressing the miR-92a expression in KYSE410 cells transfected with anti-miR-92a (Fig. 3C) . To further determine the relationship between CDH1 and miR-92a in ESCC tumor tissues, the level of CDH1 protein was measured by IHC in 62 ESCC samples for which the corresponding FFPE tumor tissues and normal adjacent tissues were available. It was found that the level of CDH1 was markedly lower in tumor tissues than that in normal adjacent tissues: 32 of 62 tumor tissues were scored as negative whereas only 1 of 62 normal esophageal epithelia was negative (p < 0.001). Moreover, 67% (22 of 33) tumor tissues with high miR-92a levels showed negative CDH1 expression; whereas only 34% (10 of 29) tumor tissues of low miR-92a level were CDH1 negative (p= 0.011) (Fig. 3D) . These results indicated that CDH1 is a target of miR-92a in ESCC cells.
miR-92a Directly Targets CDH1 3'UTR-To further investigate whether miR-92a directly target the 3'UTR of CDH1 mRNA, we performed dual luciferase reporter assay. The reporter plasmid pMIR-CDH1-Wt was transfected 24 h after transfection of pre-miR-92a to KYSE410 cells and transfection of anti-miR-92a to EC9706 cells. A significant decrease in relative luciferase activity was observed in KYSE410 cells transfected with pre-miR-92a versus negative control (Fig. 4B) . In contrast, luciferase activity significantly increased in EC9706 cells transfected with anti-miR-92a versus negative control (Fig. 4C) . Furthermore, site specific mutation of nucleotides in the miR92a binding sequence of CDH1 3'UTR abrogated the responsiveness of the reporters to both overexpression and down-regulation of miR-92a ( Fig. 4B and 4C ), indicating that 3' UTR of CDH1 mRNA is a direct target of miR-92a.
CDH1 Plays a Critical Role in miR-92a-mediated Invasion and Migration in ESCC Cells-
CDH1 has been proven to play a critical role in cell migration and invasion. We confirmed that knock-down of CDH1 expression by siRNA markedly promoted migration and invasion of KYSE410 cells (Fig. 5A) . To demonstrate the contribution of CDH1 to the biological function of miR-92a, we examined whether reconstitution of miR-92a-resistant CDH1 has an effect on miR92a-induced cell migration and invasion in KYSE410 cells. To test this, an expression vector, which carries CDH1 coding sequence but lacks the 3'UTR including the putative miR-92a target site, was co-transfected into KYSE410 cells along with pre-miR-92a. It was showed that constitutive expression miR-92a-resistant CDH1 abrogated the effect of miR-92a on cell invasion and migration (Fig. 5B) . This demonstrated that inhibition of CDH1 expression is at least partially responsible for the miR-92a ability to promote cell invasion and migration, and consequently lymph node metastasis in human ESCC.
DISSCUSSION
we recently reported that the pattern of seven miRNAs (miR-25, miR-424, miR-151, miR-100, miR-99a, miR-29c and miR-140) expressed in ESCC tissues is different from adjacent normal tissues (22) . In addition, we reported that miR-103/107 have a potential to serve as a prognostic marker (22) , which is consistent with other recent studies in which miR-103/107/129 play a role in the development and progression of Barrett's associated adenocarcinoma and ESCC (20, 24) . In this study we showed that the relative expression of miR-92a is significantly correlated with lymph node metastasis and TNM stage of ESCC patients. Thus, like miR-103/107/129, the relative expression level of miR-92a is associated with the lymph node invasion and lymph node metastasis of ESCC.
Cell motility and invasion is required for the dissemination of tumor cells from their primary location to lymph or blood vessels during metastasis. Several miRNAs were found to exhibit pro-metastatic (miR-10b, -21, and -373/520c) or anti-metastatic (miR-34b/c, -126, -148a, -206, and -335) activity (8, 25, 26) . Our data showed that miR-92a promotes cell migration and invasion, but not cell apoptosis and proliferation, which is consistent with our tissue correlation study in which the level of miR-92a is associated with lymph note metastasis, but not the T stage and the size of tumors (Table1). These findings suggest that miR-92a exerts its impact on ESCC progression through promoting the metastatic ability of ESCC tumor cells.
The biological function of miR-92a has been examined through identification of miR-92a targets. miR-92a was found to modulate KCC2 expression and thus regulate maturation of rat cerebellar granule neurons (27) . In mouse models of limb ischemia and myocardial infarction, miR92a was reported to repress expression of integrin subunit alpha5 and thus block the potential angiogenesis of endothelial cells (28). In 32D myeloid cells, miR-92a was found to regulate deltaNp63beta, a member of the p53 family, leading to increased cell proliferation and decreased cell death (29) . Moreover, in CLL B cells, miR-92a decreases pVHL expression, leading to accumulation of HIF1a and subsequently VEGF (30) . Estrogen receptor beta1 was demonstrated to be the target of miR-92a in breast cancer (31) . Our current finding indicated that miR-92a represses the expression of CDH1 in ESCC. It has been proven that loss of expression and/or abnormal function of CDH1 lead to loss of cell polarity and derangement of normal tissue architecture (32, 33) .
In most cancers with epithelial origins, CDH1-mediated cell-cell adhesion is lost concomitantly with acquisition of an invasive phenotype, high tumor grade, and low patient survival (34) (35) (36) (37) (38) (39) . Loss or reduction of CDH1 expression can be caused by a variety of mechanisms, such as somatic mutations, chromosomal deletions, proteolytic cleavage, and silencing of the CDH1 promoter (40-42). Recent studies showed that the miR-200 and miR-205 families regulate ZEB1/δEF1 and B2/SIP1 transcription repressors, which in turn regulate CDH1 expression (43,44). Moreover, miR-9, which is directly bound and up-regulated by MYC and MYCN in breast cancer cells, directly targets CDH1, leading to increased cell motility and invasiveness(45) Our study revealed a novel mechanism by which CDH1 is regulated. We showed that CDH1 is directly targeted by miR-92a in ESCC cell lines. In addition, we uncovered an inverse correlation between miR-92a and CDH1 in ESCC tumor tissues and cell lines. Furthermore, restoration of CDH1 expression inhibited cell invasion and migration induced by miR-92a overexpression, indicating that CDH1 functions as a mediator of miR-92a in cell migration and ESCC progression. Nevertheless, we would like to note that the decrease in CDH1 expression was observed more commonly than the increase in miR-92a expression in ESCC tumor tissues, suggesting that CDH1 is regulated by a mechanism in addition to miR-92a in ESCC, which merits further investigation. . Shown is Kaplan-Meier overall survival curves of two group patients, Log-rank test was used. FIGURE 2. miR-92a modulates cell migration and invasion in ESCC cells. A, KYSE410 cells were transfected with 30 nM pre-miR-92a and pre-miR-negative control (pre-miR-nc), 12 h after transfection, cells were starved with serum-free medium for 12 h, then cells were suspended with serum-free medium and seeded into transwell inserts at the density of 5×10 4 cells/wells. 24 h later, cells in the upper chamber were removed and cells that had migrated onto the lower surface of the membrane were stained and cells in three different areas at 100-fold magnification were counted. Cells transfected with premiR-92a and pre-miR-nc for 48 h were harvested for detection of miR-92a expression by qRT-PCR, RNU6B servered as internal control (right). B, EC9706 cells were transfected with 30 nM anti-miR-92a and anti-miR-negative control (anti-miR-nc), and cell migration was assessed as described in panel A. C, KYSE410 cells were transfected with 30 nM pre-miR-92a and pre-miR-nc, 12 h after transfection, cells were starved with serum-free medium for 12 h. Then cells were suspended with serum-free medium and seeded into transwell inserts coated with matrigel at the density of 5×10 4 cells/wells. 24 h later, cells that had invaded onto the lower surface of the membrane were stained and numbered. D, KYSE410 were transfected with 30 nM pre-miR-nc and pre-miR-92a, and EC9706 were transfected with anti-miRnc and anti-miR-92a. 48 h after transfection, cells were collected for apoptosis anslysis by annexin V staining and flow cytometry. E, KYSE410 were transfected with 30 nM pre-miR-nc and pre-miR-92a, and EC9706 were transfected with anti-miR-nc and anti-miR-92a. 24 h after transfection, cells were seeded into 96-well plates in octuple at the density of 1×10 3 cells per well. Cell viability was detected using WST-8 reagent of cell counting kit-8 (CCK-8) at day 1, 3, and 5 after seeded; the proliferation curve was generated based on the absorbance and times. Columns, mean for three experiments, bars, S.E., **, p < 0.01, ***, p < 0.001. predicted that CDH1 might be a target for miR-92a, and the 3' UTR of human CDH1 mRNA contains a highly conserved binding site from position 499 to 524 for miR-92a. B, The expression of miR-92a in KYSE150, KYSE410, KYSE450, EC9706 and KYSE510 cells were detected by qRT-PCR, RNU6B served as internal control (top). The cell lysates of KYSE150, KYSE410, KYSE450, EC9706 and KYSE510 cells were prepared for Western blotting using antibody against CDH1; GAPDH was used as a loading control. The gray density was quantified using LANE 1D Analyzer V4.0 software (Beijing Sage Creation). Pearson's chi-square test was used, r= -0.870; p= 0.028. C, KYSE410 cells were transfected with 30 nM pre-miR-nc and pre-miR-92a or anti-miR-nc and anti-miR-92a for 48 h. Some of cells were collected for Western blotting using antibody against human CDH1 and GAPDH was used as a loading control (top). The gray density was quantified using LANE 1D Analyzer V4.0 software. Some of cells were collected for isolation of total RNA, and 20 μg total RNA was loaded on each lane for Northern blotting, RNU6 severed as a loading control. miR-92a expression was detected by qRT-PCR, RNU6B served as internal control (bottom). D. The expression of CDH1 in tumor tissues (T) and normal adjacent tissues (NAT) was examined by IHC. These sections were also stained by hematoxylin and eosin (H&E staining). The correlation between miR-92a level and CDH1 expression was analyzed by χ 2 test, n= 62, p= 0.011 (100-fold and 200-fold indicates the magnification times). 
